G&E Herbal Biotechnology Co., Ltd. (TPEX:4911)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
35.15
+0.20 (0.57%)
Apr 29, 2026, 1:30 PM CST
-30.35%
Market Cap 2.24B
Revenue (ttm) 309.13M
Net Income (ttm) 139.20M
Shares Out 63.72M
EPS (ttm) 2.18
PE Ratio 16.12
Forward PE n/a
Dividend 1.17 (3.34%)
Ex-Dividend Date Jul 29, 2025
Volume 27,158
Average Volume 76,655
Open 36.50
Previous Close 34.95
Day's Range 34.60 - 36.50
52-Week Range 33.00 - 56.60
Beta -0.72
RSI 41.60
Earnings Date May 8, 2026

About G&E Herbal Biotechnology

G&E Herbal Biotechnology Co., Ltd. engages in manufacturing and wholesale of western and chinese medicine, cosmetics, intellectual property rights, biotechnology services, medical device, and other unclassified food products in Taiwan. It offers HepaGent capsules, a liver protective agent; botanical food supplements; botanical anti-aging cosmetics, such as facial cleansing essence, botanic extract toner, moisturizing cream and serum, and essential oil; smile cream and topical gel; as well as lubricants. G&E Herbal Biotechnology Co., Ltd. was fo... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2002
Employees 39
Stock Exchange Taipei Exchange
Ticker Symbol 4911
Full Company Profile

Financial Performance

In 2025, G&E Herbal Biotechnology's revenue was 309.13 million, an increase of 24.13% compared to the previous year's 249.03 million. Earnings were 139.20 million, an increase of 36.38%.

Financial Statements

News

There is no news available yet.